

## **RADIOPHARM APPOINTS HESTER LARKIN AS NON-EXECUTIVE DIRECTOR**

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce the appointment of Hester Larkin to its Board as a Non-Executive Director.

Ms Larkin will commence the role on February 3, 2022, after a 30-year career spanning both pharmaceuticals and nuclear medicine across Europe, Middle East & Africa, including over 12 years of experience in senior leadership roles in the industry.

She brings a proven track record of delivering significant corporate revenues and earnings and leading successful product launches of proprietary pharmaceuticals and imaging agents in oncology, cardiology, neurology and HIV.

Ms Larkin is currently Managing Director of Hester Larkin Associates Consulting where she provides consulting services to diagnostic imaging, pharmaceutical and biotech companies lending her expertise to projects ranging from pre-clinical, clinical, EMA submission, EU medical advisory boards, EU manufacturing and commercial partnerships. She has held several Board Director and Trustee positions in the UK and Belgium and currently sits on the Board of 3 Charities. She was a business consultant at the Cardiac Imaging Department, Wellington Hospital when it launched the first Electron Beam CT (EBCT) centre.

Prior to this Ms Larkin was EMEA General Manager BMS Medical Imaging at Bristol-Myers Squibb and had a 19-year career at DuPont Pharmaceuticals holding several roles in European marketing, European Business development and General Management & VP positions. She was the first non-American female to be appointed as Managing Director & Vice President UK & Ireland for Dupont Pharmaceuticals.

For 7 years Ms Larkin also chaired an Industry Working Group on Nuclear Medicine Awareness for ‘Nuclear Medicine Europe-the Industry Association,’ formerly AIPES.

With a legal background Ms Larkin has experience in governance, risk, acquisitions, mergers, licensing & divestitures.

Ms Larkin has a Bachelor of Laws from London, a Bachelor of Psychology from Queens University in Belfast and is a qualified leadership coach.

Radiopharm’s CEO & Managing Director Riccardo Canevari said: “Hester’s impressive leadership capabilities and her extensive background in the pharmaceuticals and medical imaging industry makes her a valuable addition to our Board of Directors as we steer Radiopharm through a pivotal period of innovation and growth.”

**Authorised on behalf of the Radiopharm Theranostics board of directors by Chairman Paul Hopper.**

**ASX ANNOUNCEMENT  
2 FEBRUARY 2022**



**For more information:**

Riccardo Canevari  
CEO & Managing Director  
P: +1 862 309 0293  
E: rc@radiopharmtheranostics.com

Paul Hopper  
Executive Chairman  
P: +61 406 671 515  
E: paulhopper@lifescienceportfolio.com

Media

Matt Wright  
NWR Communications  
P: +61 451 896 420  
E: matt@nwrcommunications.com.au

**Follow Radiopharm Theranostics:**

Website – <https://radiopharmtheranostics.com/>

Twitter – <https://twitter.com/TeamRadiopharm>

Linked In – <https://www.linkedin.com/company/radiopharm-theranostics/>